{"download_date": ["ClinicalTrials.gov processed this data on May 09, 2023"], "link_text": ["Link to the current ClinicalTrials.gov record."], "url": ["https://clinicaltrials.gov/show/NCT05380882"], "org_study_id": ["TQB2930-I-01"], "nct_id": ["NCT05380882"], "brief_title": ["Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers"], "official_title": ["A Phase I Study of TQB2930 Injection in Patients With Advanced Cancers"], "lead_sponsor": [], "source": ["Chia Tai Tianqing Pharmaceutical Group Co., Ltd."], "is_fda_regulated_drug": ["No"], "is_fda_regulated_device": ["No"], "textblock": ["TQB2930 is an anti-HER2 (Human Epidermal Growth Factor Receptor 2) bispecific antibody that\r\n      can simultaneously bind two epitopes of HER2, leading to a dual HER2 signal blockage. This is\r\n      a phase I study to evaluate the safety, tolerability and effectiveness of TQB2930 injection\r\n      in subjects with advanced malignancies."], "overall_status": ["Recruiting"], "type": ["Anticipated", "Anticipated", "Anticipated", "Anticipated", "Actual", "Actual"], "start_date": ["May 2022"], "completion_date": ["December 2023"], "primary_completion_date": ["April 2023"], "phase": ["Phase 1"], "study_type": ["Interventional"], "has_expanded_access": ["No"], "allocation": [], "intervention_model": ["Single Group Assignment"], "primary_purpose": ["Treatment"], "masking": ["None (Open Label)"], "measure": ["Dose Limiting Toxicity (DLT)", "Maximum tolerated dose (MTD)", "Adverse events (AE) rate", "immunogenicity", "Pharmacokinetics: The area under the curve (AUC)", "Pharmacokinetics:Peak concentration (Cmax)", "Pharmacokinetics: T1/2", "Objective Response Rate (ORR)", "Disease control rate (DCR)", "Duration of Response (DOR)", "Progression-free survival (PFS)", "Overall survival(OS)"], "time_frame": ["At the end of Cycle 1 (each cycle is 21 or 28 days)", "At the end of Cycle 1 (each cycle is 21 or 28 days).", "From date of the first dose until the date of 28 days after last dose or new anti-tumor treatment, whichever came first.", "Cycle 1 Day 1, Cycle 2 Day1, Cycle 4 Day1, Cycle 7 Day1, Cycle 12 Day1: pre-dose and end of the infusion.(each cycle is 21 or 28 days)", "Cycle1Day1, Cycle1Day8, Cycle1Day815, Cycle2 Day1, Cycle2Day8, Cycle2Day15 and Cycle3Day1: pre-dose, Cycle1Day1:at 0.5, 4, 8, 24, 48, 72, and 240 hours after infusion. Cycle2Day1:at 0.5, 4, 8, 24, 48, 72, and 240 hours after infusion.(21 or 28 days each)", "Cycle1Day1, Cycle1Day8, Cycle1Day815, Cycle2 Day1, Cycle2Day8, Cycle2Day15 and Cycle3Day1: pre-dose, Cycle1Day1:at 0.5, 4, 8, 24, 48, 72, and 240 hours after infusion. Cycle2Day1:at 0.5, 4, 8, 24, 48, 72, and 240 hours after infusion.21 or 28 days each", "Cycle1Day1, Cycle1Day8, Cycle1Day815, Cycle2 Day1, Cycle2Day8, Cycle2Day15 and Cycle3Day1: pre-dose, Cycle1Day1:at 0.5, 4, 8, 24, 48, 72, and 240 hours after infusion. Cycle2Day1:at 0.5, 4, 8, 24, 48, 72, and 240 hours after infusion.21 or 28 days each", "From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100weeks", "From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100weeks", "From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100weeks", "From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100weeks", "From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100weeks"], "description": ["DLT will be defined as toxicities that meet pre-defined severity criteria(according to the NCI CTCAE v5.0 toxicity assessment criteria), and assessed as having a suspected relationship to study drug that occurred from the first dose to the end of the first treatment cycle.", "MTD was defined as the highest dose at which dose-limiting toxicity (DLT) occurred in less than 33% of patients.", "The occurrence and severity of all AEs", "Incidence of anti-drug antibody (ADA)", "The area under the curve (AUC) of serum concentration of TQB2930", "Maximum observed concentration (Cmax) of TQB2930", "Terminal half-life (T1/2)", "Defined as the percentage of Complete Response (CR) plus partial response (PR) assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria", "Defined as the proportion of subjects with CR, PR, or SD (Stable Disease).", "Defined as the time from first documented response to documented disease progression.", "Defined as the time from the first dose of TQB2928 to the first occurrence of disease progression or death from any cause.", "Overall survival refers to the time from the first treatment to death from any cause.", "Drug:Weekly intravenous infusion of TQB2930 injection,21 days as a treatment cycle. (2.5mg/kg, 5mg/kg, 10mg/kg) Drug:Every two weeks intravenous infusion of TQB2930 injection , 28 days as a treatment cycle.(20mg/kg) Drug:Every three weeks intravenous infusion of TQB2930 injection, 21 days as a treatment cycle. (30mg/kg)", "TQB2930 is an anti-HER2 bispecific antibody."], "number_of_arms": [1.0], "enrollment": [60.0], "condition": ["Advanced Cancers"], "arm_group_label": ["TQB2930 injection", "TQB2930 injection"], "arm_group_type": ["Experimental"], "intervention_type": ["Drug"], "intervention_name": ["TQB2930 injection"], "criteria": [], "gender": ["All"], "minimum_age": ["18 Years"], "maximum_age": ["75 Years"], "healthy_volunteers": ["No"], "last_name": ["Ruihua Xu, Doctor"], "phone": ["86-20-87343468"], "email": ["ruihxu@163.com"], "facility": [], "status": ["Recruiting"], "contact": [], "country": ["China"], "verification_date": ["May 2022"], "study_first_submitted": ["May 6, 2022"], "study_first_submitted_qc": ["May 18, 2022"], "study_first_posted": ["May 19, 2022"], "last_update_submitted": ["May 18, 2022"], "last_update_submitted_qc": ["May 18, 2022"], "last_update_posted": ["May 19, 2022"], "responsible_party_type": ["Sponsor"], "mesh_term": ["Neoplasms"]}